

Provider Participation Agreement

To receive federally funded Section 317 COVID-19 vaccines provided through the California Bridge Access Program at no cost, I agree to the following conditions, on behalf of myself and all the practitioners, nurses, and others associated with the health care location of which I am the medical director or equivalent.

1. COVID-19 vaccines will be administered to any individual aged 19 years and older who is uninsured or underinsured. Insured patients, including patients covered by Medicare and Medi-Cal, are NOT eligible for COVID-19 vaccines provided through the Bridge Access Program (hereafter referred to as BAP). Staff will consult the [BAP Eligibility Based on Insurance Status](#) table as needed to determine specific vaccine eligibility for patients. Eligibility screening will be conducted prior to the administration of vaccine doses. Verification of eligibility may be obtained verbally from the individual. All staff, including front office and billing staff, will be knowledgeable of BAP eligibility.
2. COVID-19 vaccines will be administered in compliance with the most recent immunization schedule, dosage, and contraindications established by the Advisory Committee on Immunization Practices (ACIP) and in compliance with all applicable requirements as set forth by the U.S. Food and Drug Administration (FDA), including but not limited to requirements in any Emergency Use Authorization (EUA) fact sheet that covers COVID-19 vaccine.
3. Patients immunized with BAP-supplied vaccines will not be billed for the cost of the vaccine nor be charged an administration fee. All systems will be checked to ensure patients are not charged and vaccine cost will not be billed.
4. Before administering COVID-19 vaccine, an approved EUA fact sheet or vaccine information statement (VIS) will be provided as required to each vaccine recipient, the adult caregiver accompanying the recipient, or other legal representative. Vaccine administration records will be maintained in accordance with the National Childhood Vaccine Injury Act (NCVIA), which includes reporting clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) <https://vaers.hhs.gov/>.
5. Within 24 hours of administering a dose of COVID-19 vaccine to a BAP-eligible patient, administration data will be recorded in the recipient's permanent medical record and submitted to the State's Immunization information System (CAIR2 or Healthy Futures/RIDE) no later than 72 hours; providers must ensure that the proper vaccine eligibility category "317" is documented in CAIR.
6. The total number of patients immunized with COVID-19 vaccines and current inventory on hand will be reported to the California Department of Public Health (CDPH) according to the BAP reporting guidelines. The patient's recorded BAP 317 eligibility status and all records related to the Bridge Access Program will be retained for three (3) years. If requested, patient records will be made available to CDPH. Records include, but are not limited to, vaccine administration documentation, billing records, and medical records that verify receipt of vaccine. Release of such records will be bound by federal and state privacy laws.
7. Order vaccines according to the BAP ordering guidance; providers who have not ordered vaccines in a period longer than 6 months may be terminated from the Bridge Access Program.
8. The location will comply with all requirements for COVID-19 vaccine management and reporting including the following:
 - A. Store and handle COVID-19 vaccines under proper conditions, including maintaining cold chain conditions and chain of custody at all times in accordance with the manufacturer's package insert, Fact

Sheet for Healthcare Providers Administering the Vaccine, and guidance in CDC's [Vaccine Storage and Handling Toolkit and COVID-19 Addendum](#).

- B. Monitor and record vaccine storage unit temperatures twice daily following guidance in CDC's [Vaccine Storage and Handling Toolkit and COVID-19 Addendum](#).
 - C. Respond to and report temperature excursions following CDPH guidance.
 - D. Monitor and comply with COVID-19 vaccine expiration and beyond-use dates; never administer expired vaccine.
 - E. Preserve all records related to COVID-19 vaccine management (e.g., vaccine temperature logs, invoices, and packing slips) for a minimum of 3 years.
 - F. Report the number of doses of COVID-19 vaccine and adjuvants that were unused, spoiled, expired, or wasted following CDPH guidance.
 - G. Return all nonviable vaccine to McKesson following CDPH guidance.
 - H. Never borrow BAP-supplied vaccines to supplement private stock, or vice versa.
 - I. Never routinely redistribute BAP-supplied vaccines; report emergency/unplanned vaccine transfers following CDPH guidance.
 - J. Vaccinators, clinicians, vaccine coordinators, and other staff who store, handle, or administer COVID-19 vaccine must complete the required vaccine product training before receiving shipments to ensure they are prepared to maintain vaccines under proper conditions.
9. Update [Vaccines.gov](#) to indicate BAP vaccine availability and make our location profile public according to CDC data guidance and timelines.
10. The location will operate in a manner intended to avoid fraud and abuse of COVID-19 vaccines supplied through the Bridge Access Program.
- Fraud** is an intentional deception or misrepresentation made by a person with the knowledge that the deception could result in some unauthorized benefit to himself or some other person. It includes any act that constitutes fraud under applicable federal or state law.
- Abuse** is defined as provider practices that are inconsistent with sound fiscal, business, or medical practices and result in an unnecessary cost to the program or in reimbursement for services that are not medically necessary or that fail to meet professionally recognized standards for health care.
11. Authorized CDPH representatives will be permitted to visit the location to review compliance with all BAP policies and procedures; provider agrees to implement and complete corrective actions identified during the visit.
12. The term of this agreement is valid from enrollment through December 31, 2024, or until vaccine supply doses are completely depleted. COVID-19 vaccines supplied through the Bridge Access Program may continue to be administered until their expiration date.
13. I understand that either the CDPH Immunization Branch or my location/organization may terminate this agreement at any time. If the agreement is terminated, any unused COVID-19 vaccines will be properly returned to the CDPH Immunization Program, which administers the Bridge Access Program.

By signing this form, I certify, on behalf of myself and all immunization providers in this location, that I have read and agree to the requirements listed above and understand I am accountable (and each listed provider is individually accountable) for compliance with these requirements.

Chief Executive Officer

Name	
Signature	
Date	

Chief Medical Officer

Name	
Medical License Number	
Signature	
Date	

Vaccine Coordinator

Name	
Signature	
Date	